From The Year-End Conference Calls....
Executive Summary
Lilly GMP issues: Lilly will be "inspection-ready" at the Cymbalta dry products facility in the first quarter, with the Zyprexa IM parental facility FDA-ready "some time later," Exec Director-Investor Relations Simon Harford tells Jan. 23 conference call. "Whether they will have a date specified up-front or whether they will just arrive, which they have the right to do, is still yet to be determined." Although Lilly acknowledged that "significant dialogue" with FDA remains, "as time goes on, I think we feel a bit more positive about our situation on the manufacturing side," CFO Charles Golden says. "We've had no discussions whatsoever about a consent decree with them"...
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Pfizer Darifenacin Will Be Divested As Condition For EU Approval Of Merger
Pfizer's pending urinary incontinence therapy darifenacin is the most significant asset the company needs to divest as a condition of the European approval of the Pharmacia merger